A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis

Peer Review reports

Original Submission
19 Jul 2017	Submitted	Original manuscript
20 Jun 2017	Reviewed	Reviewer Report - John Vizuete
20 Jun 2017	Reviewed	Reviewer Report - Yaron Rotman
22 Jun 2017	Reviewed	Reviewer Report - Fernando Bril
21 Aug 2017	Reviewed	Reviewer Report - Joseph Raybon
13 Oct 2017	Reviewed	Reviewer Report - Vittal Shivva
23 Nov 2017	Author responded	Author comments - Melissa Palmer
Resubmission - Version 2
23 Nov 2017	Submitted	Manuscript version 2
6 Dec 2017	Author responded	Author comments - Melissa Palmer
Resubmission - Version 3
6 Dec 2017	Submitted	Manuscript version 3
Publishing
7 Mar 2018	Editorially accepted
16 Mar 2018	Article published	10.1186/s40360-018-0200-y

Back to article page